NLGN3 (Neuroligin-3) encodes a postsynaptic cell adhesion molecule that is essential for the formation, function, and plasticity of synapses throughout the mammalian brain. As a member of the neuroligin family, NLGN3 mediates trans-synaptic adhesion by binding to presynaptic neurexins (NRXN1, NRXN2, NRXN3), forming a physical bridge that aligns presynaptic release machinery with postsynaptic signaling apparatus [1]. NLGN3 is widely expressed in neurons throughout the brain, with particularly high levels in the cerebral cortex, hippocampus, and basal ganglia.
Mutations in NLGN3 were among the first gene discoveries in monogenic autism spectrum disorder (ASD), establishing a direct link between synaptic adhesion molecules and social cognition [2]. The R451C substitution in NLGN3 causes a missense mutation that alters the protein's ability to form inhibitory synapses, providing a molecular basis for the excitatory/inhibitory imbalance hypothesis of autism. Beyond ASD, NLGN3 is implicated in Alzheimer's disease (AD) and Parkinson's disease (PD), where amyloid-beta and alpha-synuclein pathology, respectively, disrupt NLGN3-mediated synaptic adhesion, contributing to synaptic dysfunction and cognitive decline [3][4].
| Property | Value |
|---|---|
| Gene Symbol | NLGN3 |
| Full Name | Neuroligin 3 |
| Chromosomal Location | Xq13.1 |
| NCBI Gene ID | 54413 |
| OMIM ID | 300336 |
| Ensembl ID | ENSG00000174373 |
| UniProt ID | Q9NZU4 |
| Gene Size | ~36 kb |
| Exons | 19 |
| Protein Length | 1,461 amino acids |
| Molecular Weight | ~165 kDa |
NLGN3 is a type I transmembrane protein with distinct structural domains [1:1]:
NLGN3 undergoes extensive alternative splicing, with at least three principal isoforms identified:
The splice site at intron 7 (site A) and intron 15 (site B) produce isoforms with different properties. Site A insertion influences neurexin-binding affinity, while site B affects intracellular protein interactions.
NLGN3 functions as a master organizer of synaptic connectivity through its interaction with presynaptic neurexins [1:2]:
Neurexin Binding Mechanism:
Synapse Formation Pathway:
NLGN3 contributes to the molecular code that specifies synapse types:
| Synapse Type | NLGN3 Contribution | Key Partners |
|---|---|---|
| Excitatory (glutamatergic) | Moderate | NLGN1, NRXN1α |
| Inhibitory (GABAergic) | High | NLGN2, NRXN1β |
| Mixed/ambiguous | Specific | Multiple NRXN isoforms |
Unlike NLGN1 (excitatory-specific) and NLGN2 (inhibitory-specific), NLGN3 contributes to both excitatory and inhibitory synapses, conferring unique flexibility in synaptic circuit organization.
NLGN3 is dynamically regulated by synaptic activity and plays a critical role in experience-dependent plasticity [5:1][6]:
The NLGN3 intracellular domain recruits multiple signaling proteins:
NLGN3 mutations represent one of the most robust genetic links to monogenic autism [2:1][8]:
R451C Missense Mutation:
The R451C substitution (arginine to cysteine at position 451) was identified in Swedish families with ASD and intellectual disability. Functional studies revealed:
Additional ASD-Associated Mutations:
Mechanistic Insights:
NLGN3 is progressively downregulated in AD brain tissue, contributing to synaptic failure [3:1][12]:
NLGN3 alterations in PD reflect synaptic vulnerability in dopaminergic circuits [4:1]:
NLGN3 mutations cause X-linked intellectual disability with variable phenotypes:
The structural basis of neurexin-neuroligin adhesion involves:
Key features:
Upon neurexin binding, NLGN3 triggers intracellular signaling:
NLGN3 is dynamically regulated by neural activity [5:2]:
| Protein | Interaction Type | Functional Consequence |
|---|---|---|
| NRXN1 (Neurexin-1) | Trans-synaptic adhesion | Primary synapse organizer |
| NRXN2 (Neurexin-2) | Trans-synaptic adhesion | Synapse specificity |
| NRXN3 (Neurexin-3) | Trans-synaptic adhesion | Alternative partner |
| PSD-95 (DLG4) | PDZ-domain binding | Postsynaptic scaffold |
| SAP97 (DLG1) | PDZ-domain binding | Receptor trafficking |
| Shank1/2/3 | Indirect (via PSD-95) | Cytoskeletal linkage |
| Homer1/2/3 | Indirect via scaffold | mGluR signaling |
| Dystrophin | Alternative scaffold | Specializes synapses |
In Alzheimer's Disease:
In Parkinson's Disease:
Nlgn3 knockout mice exhibit:
The autism-associated R451C mutation in knock-in mice [7:2][9:1]:
Conditional deletion in adulthood [13]:
Gene therapy approaches have demonstrated [14]:
NLGN3 represents a promising target for monogenic autism [14:1]:
NLGN3 and its interacting proteins serve as synaptic biomarkers:
High expression in:
Lower expression in:
| Cell Type | NLGN3 Expression | Synaptic Localization |
|---|---|---|
| Pyramidal neurons | High | Dendritic spines, shaft |
| GABAergic interneurons | High | Perisomatic, dendrites |
| Dopaminergic neurons | Moderate | Axonal varicosities |
| Astroglia | Low | Not synaptic |
| Oligodendrocytes | Very low | Not applicable |
Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008. ↩︎ ↩︎ ↩︎
Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4X cause autism. Proceedings of the National Academy of Sciences. 2003. ↩︎ ↩︎
Giacomucci G, Mazzascala L, Gerace F, et al. Neuroligin-3 deficiency and impaired homeostatic synaptic plasticity in Alzheimer's disease. Acta Neuropathologica Communications. 2017. ↩︎ ↩︎
Bissiere S, Dorronsoro I, Ahn H, et al. Reduced neuroligin-3 in Parkinson's disease frontal cortex reflects synaptic loss. Neurobiology of Disease. 2021. ↩︎ ↩︎
Varea O, Martin-de-Saavedra MD, Kortleven C, et al. Rapid and coordinated regulation of neuroligin function by synaptic activity. Journal of Neuroscience. 2010. ↩︎ ↩︎ ↩︎
Bethe A, Fischer T, Fauster C, et al. Neuroligin-3 is required for the plasticity of inhibitory circuits in the autism brain. Cell Reports. 2015. ↩︎
Tabuchi K, Blundell J, Etherton MR, et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007. ↩︎ ↩︎ ↩︎
Nava C, Ruelle A, Doummar D, et al. Associations of neuroligin mutations with autism and neurodevelopmental phenotypes. Journal of Human Genetics. 2014. ↩︎
Tanaka KF, Matsui K, Yasumizu M, et al. NLGN3 R451C knock-in mice exhibit altered social behavior and GABAergic synapse function. Journal of Comparative Neurology. 2012. ↩︎ ↩︎
Bemben MA, Nguyen QTA, Nicoll R, et al. Autism spectrum disorder associated mutations in neuroligin lead to distinct functional outcomes. Journal of Biological Chemistry. 2015. ↩︎
Kumar RA, KaraMohamed S, Sudi J, et al. Recurrent 15q11.2 BP1-BP2 microdeletions encompassing TJP1 and NLGN3 candidate genes in autism. Human Genetics. 2013. ↩︎
Duke D, McGowan A, Hunt S, et al. Synaptic proteins as biomarkers of Alzheimer's disease progression. Acta Neuropathologica. 2020. ↩︎
Sun C, Cheng MC, Qin R, et al. Deletion of neuroligin-3 in adult mice impairs memory and synaptic plasticity. Hippocampus. 2019. ↩︎
Rodriguez-Palmero A, Boerrigter MM, Hauer D, et al. Rescue of NLGN3 loss-of-function by AAV-mediated gene therapy in a mouse model of autism. Molecular Therapy Methods and Clinical Development. 2022. ↩︎ ↩︎